secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-04-12T23:59:59+00:00
Accession:  0001193125-24-094875
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix prices upsized $175M public offering of 10.17M shares and prefunded warrants at $15.00/share
--------------------------------------------------------------------------------

- 10,166,667 common shares at $15.00/share plus 1,500,100 pre-funded warrants at $14.999/warrant.
- Gross proceeds of $175M; net proceeds estimated at ~$164M after underwriting discounts and expenses.
- Proceeds to fund clinical development, R&D pipeline expansion, and working capital.
- Underwriters granted 30-day option to purchase up to an additional 1.75M shares.
- Offering expected to close on or about April 16, 2024, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312524094875/0001193125-24-094875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312524094875/d818273d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-094875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer